GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Research & Development

RGC (Regencell Bioscience Holdings) Research & Development : $1.07 Mil (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Regencell Bioscience Holdings's Research & Development for the six months ended in Jun. 2024 was $0.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was $1.07 Mil.

Regencell Bioscience Holdings Research & Development Historical Data

The historical data trend for Regencell Bioscience Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Research & Development Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial 0.39 0.44 2.51 1.58 1.07

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 1.40 1.35 0.23 0.49 0.58

Regencell Bioscience Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings  (NAS:RGC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Regencell Bioscience Holdings Research & Development Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Research & Development
Comparable Companies
OPTN RMTI CTOR INCR MRMD ASRT DERM ETST SCYX IXHL ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Website
https://www.regencellbioscience.com
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.